

Leading Driver In The Lysosomal Enzyme Market 2025: Rising Healthcare Expenditure Fuels Growth In Therapy (ERT) Market

*The Business Research Company's
Lysosomal Enzyme Global Market Report
2025 – Market Size, Trends, And Global
Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, July 1, 2025

/EINPresswire.com/ -- Save 30% On All
Global Market Reports With Code

ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.



The Business
Research Company

Lysosomal Enzyme Global Market Report 2025

Where Is The Lysosomal Enzyme Market Headed?

The [lysosomal enzyme market size](#) has seen a robust growth in recent years. Proving this, the market value climbed from \$9.47 billion in 2024 to \$10.07 billion in 2025, marking a compound annual growth rate CAGR of 6.3%. This increase is attributed to a rising prevalence of lysosomal storage disorders, an increase in awareness and diagnosis rates, a growth in investment in rare disease research, supportive regulatory frameworks, the expansion of biotechnology capabilities, and greater access to orphan drugs

“

Save 30% On All Global
Market Reports With Code
ONLINE30 – Stay Informed
On Tariff Changes,
Macroeconomic Trends, And
More.”

*The Business Research
Company*

As The Lysosomal Enzyme Market Hurdles Towards A
Future Defined By Technology, What Growth Can We

Anticipate?

The upward trend isn't slowing down anytime soon. It's expected it will grow to \$12.73 billion in 2029, with a compound annual growth rate CAGR of 6.0%. What's fueling this forecasted growth? Factors include rising investments in rare disease research, an increase in gene therapy, expanding newborn screening programs, growing adoption of enzyme replacement therapies, emerging biopharmaceutical innovations, and supportive regulatory pathways for orphan drugs.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24595&type=smp>

What Are The Key Forces Driving The Lysosomal Enzyme Market Cap?

Riding on the coattails of substantial improvements in gene therapy, the lysosomal enzyme market could reach even greater heights. Gene therapy - the medical treatment that involves altering or replacing genes within a person's cells to treat or prevent disease - is becoming increasingly popular. With advances in delivery vectors and demonstrated long-term efficacy, gene therapy is now considered a viable, potentially curative option for genetic disorders. Often, gene therapy requires initial or complementary enzyme replacement treatments to manage symptoms and stabilize patients, while the gene therapy starts to make its impact. This requirement will sustain the need for lysosomal enzyme products moving forward, and in turn, boost the growth of the lysosomal enzymes market. For instance, in April 2024, there was a 10% increase in the number of phase III gene therapy clinical trials in 2023, according to the American Society of Gene & Cell Therapy, a US-based non-profit organization.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/lysosomal-enzyme-global-market-report>

Who Are The Key Players Driving Growth In The Lysosomal Enzyme Market?

Some of the major companies operating in the lysosomal enzyme market include Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Protalix BioTherapeutics Inc., Orchard Therapeutics Plc, Alexion Pharmaceuticals Inc., ISU Abxis Co. Ltd., Chiesi Farmaceutici S.p.A., GC Pharma Co. Ltd., Genzyme Corp., Shire plc, Greenovation Biotech GmbH, Oxyrane, AvroBio Inc., Ultragenyx Pharmaceutical Inc.

What Are The Innovative Trends Propelling The Lysosomal Enzyme Market Ahead Of Its Competition?

These major players are focusing on strategic partnerships to expand diagnostic capabilities and accelerate the development of novel therapies. For instance, in February 2024, a Spain-based biotechnology company partnered with Biosidus, an Argentina-based biotechnology company, to manufacture the active enzyme ingredient Agalsidase Beta. Such strategic partnerships reflect a significant advancement in developing and manufacturing treatments for rare diseases, particularly Fabry disease, caused by lysosomal enzyme deficiency.

How Is The Burgeoning [Lysosomal Enzyme Market Segmented](#)?

The lysosomal enzyme market is divided into the following segments:

1 By Type: Acid Alpha-Glucosidase, Acid Sphingomyelinase, Beta-Glucocerebrosidase, Hexosaminidase

2 By Indication: Gaucher Disease, Mucopolysaccharidosis, Pompe Disease, Other Indications

3 By Source: Recombinant Enzymes, Natural Enzymes, Synthetic Enzymes

4 By Application: Enzyme Replacement Therapy, Research And Development, Diagnostics, Gene Therapy

5 By End-Use: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies

Subsegments:

1 By Acid Alpha-Glucosidase: Pompe Disease Enzymes, Glycogen Storage Disease Type II Enzymes

2 By Acid Sphingomyelinase: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B

3 By Beta-Glucocerebrosidase: Gaucher Disease Type I, Gaucher Disease Type II, Gaucher Disease Type III

4 By Hexosaminidase: Tay-Sachs Disease Enzymes, Sandhoff Disease Enzymes

Which Regions Are Leading The Lysosomal Enzyme Market?

North America led the pack as the largest region in the lysosomal enzyme market in 2024.

However, Asia-Pacific is expected to be the fastest-growing region during the forecast period.

Browse Through More Similar Reports By [The Business Research Company](#):

Enzyme Replacement Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/enzyme-replacement-therapy-global-market-report>

Enzymes Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/enzyme-global-market-report>

Lysosomal Disease Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/lysosomal-disease-treatment-global-market-report>

About The Business Research Company: With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/827254495>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.